Antiviral treatment and vaccination for influenza A(H1N1)pdm09 virus: lessons learned from the pandemic
- PMID: 23116793
- DOI: 10.1016/S0213-005X(12)70105-2
Antiviral treatment and vaccination for influenza A(H1N1)pdm09 virus: lessons learned from the pandemic
Abstract
The influenza pandemic that was declared by the World Health Organization in June 2009 created a new scenario for the use of influenza antivirals and vaccination. The new strain, influenza A(H1N1)pdm09, was resistant to amantadine and rimantadine, and the most frequently used antiviral was oseltamivir. Randomized studies were not performed comparing neuraminidase inhibitors with placebo. Nevertheless, experience from prospective and retrospective cohorts indicated that these drugs were useful for improving the prognosis of patients admitted to hospitals, especially for those with more severe disease. Treatment with oseltamivir was associated with a reduction in days of fever, length of hospital stay, use of mechanical ventilation and mortality. Treatment was more effective if it was begun within the first 48 h after the onset of symptoms, but it was also useful if begun later. A safe and effective vaccine to prevent disease from this new influenza strain was available in developed countries soon after the pandemic began; thus, the rate of adverse effects was comparable to that of seasonal influenza vaccines. The main barrier to its use was the concern of target populations about its necessity and safety. Therefore, the challenges for future pandemics will be to increase the population coverage of the vaccine in developed countries and to make it affordable for developing countries.
Copyright © 2012 Elsevier España, S.L. All rights reserved.
Similar articles
-
Influenza A(H1N1)pdm09: beyond the pandemic.Enferm Infecc Microbiol Clin. 2012 Oct;30 Suppl 4:54-7. doi: 10.1016/S0213-005X(12)70106-4. Enferm Infecc Microbiol Clin. 2012. PMID: 23116794
-
Antiviral drugs in influenza: an adjunct to vaccination in some situations.Prescrire Int. 2006 Feb;15(81):21-30. Prescrire Int. 2006. PMID: 16548114
-
Modeling control strategies for concurrent epidemics of seasonal and pandemic H1N1 influenza.Math Biosci Eng. 2011 Jan;8(1):141-70. doi: 10.3934/mbe.2011.8.141. Math Biosci Eng. 2011. PMID: 21361405
-
Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.J Clin Virol. 2011 Oct;52(2):70-8. doi: 10.1016/j.jcv.2011.05.019. Epub 2011 Jun 17. J Clin Virol. 2011. PMID: 21684202 Review.
-
The potential for multidrug-resistant influenza.Curr Opin Infect Dis. 2011 Dec;24(6):599-604. doi: 10.1097/QCO.0b013e32834cfb43. Curr Opin Infect Dis. 2011. PMID: 22001947 Review.
Cited by
-
Amantadine and rimantadine for influenza A in children and the elderly.Cochrane Database Syst Rev. 2014 Nov 21;2014(11):CD002745. doi: 10.1002/14651858.CD002745.pub4. Cochrane Database Syst Rev. 2014. PMID: 25415374 Free PMC article. Review.
-
Exploring new antiviral targets for influenza and COVID-19: Mapping promising hot spots in viral RNA polymerases.Virology. 2023 Jan;578:45-60. doi: 10.1016/j.virol.2022.11.001. Epub 2022 Nov 18. Virology. 2023. PMID: 36463618 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical